Jump to content

Recommended Posts

I can not verify the authenticity of the below post but it was forwarded by an ICU PA I know and reportedly posted by an intensivist in Seattle:

 

“Intensivist front line in Seattle” 

* we have 21 pts and 11 deaths since 2/28. 
* we are seeing pts who are young (20s), fit, no comorbidities, critically ill. It does happen. 
* US has been past containment since January
* Currently, all of ICU is for critically ill COVIDs, all of floor medsurg for stable COVIDs and EOL care, half of PCU, half of ER. New resp-sx pts Pulmonary Clinic offshoot is open

* CDC is no longer imposing home quarantine on providers who were wearing only droplet iso PPE when intubating, suctioning, bronching, and in one case doing bloody neurosurgery. Expect when it comes to your place you may initially have staff home-quarantined. Plan for this NOW. Consider wearing airborne iso PPE for aerosol-generating procedures in ANY pt in whom you suspect COVID, just to prevent the mass quarantines.

* we ran out of N95s (thanks, Costco hoarders) and are bleaching and re-using PAPRs, which is not the manufacturer's recommendation. Not surprised on N95s as we use mostly CAPRs anyway, but still.

*terminal cleans (inc UV light) for ER COVID rooms are taking forever, Enviro Services is overwhelmed. Bad as pts are stuck coughing in the waiting room. Rec planning now for Enviro upstaffing, or having a plan for sick pts to wait in their cars (that is not legal here, sadly).

* CLINICAL INFO based on our cases and info from CDC conf call today with other COVID providers in US:

* the Chinese data on 80% mildly ill, 14% hospital-ill, 6-8% critically ill are generally on the mark. Data very skewed by late and very limited testing, and the number of our elderly pts going to comfort care. 

- being young & healthy (zero medical problems) does not rule out becoming vented or dead - probably the time course to developing significant lower resp sx is about a week or longer (which also fits with timing of sick cases we started seeing here, after we all assumed it was endemic as of late Jan/early Feb). 

- based on our hospitalized cases (including the not formally diagnosed ones who are obviously COVID 

- it is quite clinically unique) about 1/3 have mild lower resp sx, need 1-5L NC. 1/3 are sicker, FM or NRB. 1/3 tubed with ARDS. 

Thus far, everyone is seeing: 
- nl WBC. Almost always lymphopenic, occasionally poly-predominant but with nl total WBC. Doesn't change, even 10days in.

 - BAL lymphocytic despite blood lymphopenic (try not to bronch these pts; this data is from pre-testing time when we had several idiopathic ARDS cases) 

- fevers, often high, may be intermittent; persistently febrile, often for >10d. It isn't the dexmed, it's the SARS2. 
- low ProCalc; may be useful to check initially for later trending if later concern for VAP etc. 

- up AST/ALT, sometimes alk phos. Usually in 70-100 range. No fulminant hepatitis. Notably, in our small sample, higher transaminitis at admit (150-200) correlates with clinical deterioration and progression to ARDS. LFTs typically begin to bump in 2nd week of clinical course. - mild AKI (Cr <2). Uncertain if direct viral effect, but notably SARS2 RNA fragments have been identified in liver, kidneys, heart, and blood.

* characteristic CXR always bilateral patchy or reticular infiltrates, sometimes perihilar despite nl EF and volume down at presentation. At time of presentation may be subtle, but always present, even in our pts on chronic high dose steroids. NO effusions. CT is as expected, rarely mild mediastinal LAD, occ small effusions late in course which might be related to volume status/cap leak.

* Note - China is CT'ing everyone, even outpts, as a primarily diagnostic modality. However, in US/Europe, CT is rare, since findings are nonspecific, would not change management, and the ENTIRE scanner and room have to terminal-cleaned, which is just impossible in a busy hospital. Also, transport in PAPRs. Etc. 2 of our pts had CTs for idiopathic ARDS in the pre-test era; they looked like the CTs in the journal articles. Not more helpful than CXR. - when resp failure occurs, it is RAPID (likely 7-10d out from sx onset, but rapid progression from hospital admit). Common scenario for our pts is, admit 1L NC. Next 12hrs -> NPPV. Next 12-24hrs -> vent/proned/Flolan. 

- interestingly, despite some needing Flolan, the hypoxia is not as refractory as with H1N1. Quite different, and quite unique. Odd enough that you'd notice and say hmmm. 

- thus far many are dying of cardiac arrest rather than inability to ventilate/oxygenate. 

- given the inevitable rapid progression to ETT once resp decompensation begins, we and other hosps, including Wuhan, are doing early intubation. Facemask is fine, but if needing HFNC or NPPV just tube them. They definitely will need a tube anyway, & no point risking the aerosols. 

- no MOSF. There's the mild AST/ALT elevation, maybe a small Cr bump, but no florid failure. except cardiomyopathy. 

- multiple pts here have had nl EF on formal Echo or POCUS at time of admit (or in a couple of cases EF 40ish, chronically). Also nl Tpn from ED. Then they get the horrible resp failure, sans sepsis or shock. Then they turn the corner, off Flolan, supined, vent weaning, looking good, never any pressor requirement. Then over 12hrs, newly cold, clamped, multiple-pressor shock that looks cardiogenic, EF 10% or less, then either VT->VF-> dead or PEA-> asystole in less than a day. 

Needless to say this is awful for families who had started to have hope. 

- We have actually had more asystole than VT, other facilities report more VT/VF, but same time course, a few days or a week after admit, around the time they're turning the corner. This occurs on med-surg pts too; one today who is elderly and chronically ill but baseline EF preserved, newly hypoTN overnight, EF<10. Already no escalation, has since passed, So presumably there is a viral CM aspect, which presents later in the course of dz. 

- of note, no WMAs on Echo, RV preserved, Tpns don't bump. Could be unrelated, but I've never seen anything like it before, esp in a pt who had been HD stable without sepsis.

Treatment -

*Remdesivir might work, some hosps have seen improvement with it quite rapidly, marked improvement in 1-3 days. ARDS trajectory is impressive with it, pts improve much more rapidly than expected in usual ARDS.

*Recommended course is 10d, but due to scarcity all hosps have stopped it when pt clinically out of the woods - none have continued >5d. It might cause LFT bump, but interestingly seem to bump (200s-ish) for a day or 2 after starting then rapidly back to normal - suggests not a primary toxic hepatitis.

*unfortunately, the Gilead compassionate use and trial programs require AST/ALT <5x normal, which is pretty much almost no actual COVID pts. Also CrCl>30, which is fine. CDC is working with Gilead to get LFT reqs changed now that we know this is a mild viral hepatitis.

-currently the Gilead trial is wrapping up, NIH trial still enrolling, some new trial soon to begin can't remember where.

*steroids are up in the air. In China usual clinical practice for all ARDS is high dose methylpred. Thus, ALL of their pts have had high dose methylpred. Some question whether this practice increases mortality.

*it is likely that it increases seconday VAP/HAP. China has had a high rate of drug resistant GNR HAP/VAP and fungal pna in these pts, with resulting increases mortality. We have seen none, even in the earlier pts who were vented for >10d before being bronched (prior to test availability, again it is not a great idea to bronch these pts now).

- unclear whether VAP-prevention strategies are also different, but wouldn't think so?

- Hong Kong is currently running an uncontrolled trial of HC 100IV Q8.

- general consensus here (in US among docs who have cared for COVID pts) is that steroids will do more harm than good, unless needed for other indications.

- many of our pts have COPD on ICS. Current consensus at Evergreen, after some observation & some clinical judgment, is to stop ICS if able, based on known data with other viral pneumonias and increased susceptibility to HAP. Thus far pts are tolerating that, no major issues with ventilating them that can't be managed with vent changes. We also have quite a few on AE-COPD/asthma doses of methylpred, so will be interesting to see how they do.

-name removed per their request.

 

  • Upvote 1

Share this post


Link to post
Share on other sites

I'm somewhat local to the aforementioned individual.  Have seen a couple come through, one was extubated after 2 days, doing fairly well, hasn't progressed to any type of MODS phenotype.  Have run into issues with logistics/supply issues.

Sending off a request for remdesivir for one other, will see what happens!

Share this post


Link to post
Share on other sites

Also running into the problem of overtesting in the community, i.e. SNF has a patient who had a cough/runny nose so they automatically send off a COVID swab, patient is subsequently admitted for a bowel perf or seizures and guess what...because they are a r/o they get the full meal deal when they actually had seasonal allergies.  This ends up with a "for-realsies" rule out sitting in the ED boarding.  Sigh.

Share this post


Link to post
Share on other sites
Got this email.  Looks like their healthcare system is overwhelmed and likely significant staff quarantined.  
5224eeb5-237c-4333-a0fd-c42796e16f99.jpg
S.gif
 
MAPA has received a request for PAs to help in 
both Washington State and  San Carlos, CA
 
Please send ALL inquires directly to atarianna.furr@ami.health for more information
 
DO NOT CONTACT MAPA
 
Please see below the details for AMI’s response in Kirkland, Washington this upcoming Monday 15th.
 
AMI is looking for U.S. based Nurse Practitioners (NP), Physicians Assistants (PA) and Registered Nurses (RN) to join our team for an IMMEDIATE response effort in support of COVID-19. The response team will be deployed to Kirkland, Washington on the 15th of March. The team will consist of 30 registered nurses and 6 PAs/NPs. This response is in support of current efforts at the Life Care Center facility providing medical care to individuals with COVID-19 and those exposed to COVID-19. All Personal Protective Equipment (PPE) per the CDC standards will be provided. This project will be a minimum of 14 workdays. Personnel will be AMI contracted consultants under a contract AMI has with the Department of Health and Human Services. HHS already has staff onsite that will provide a handoff to our staff.
 
Location: Life Care Center in Kirkland, Washington.
Deployment date: March 15th, 2020.
Positions available: 3
Three shifts a day, each shift is 8 hours. Shifts will be 10 RNs and 2 PAs/NPs on at a time.
Travel and accommodation are covered by AMI. Accommodation in the form of hotel rooms.
Please see the rates below to share with any RN, PA, NP connections you may have.
 
Please have them contact me directly atarianna.furr@ami.health for more information.
 
Visit us online at ami.health
 
 
 

Share this post


Link to post
Share on other sites

I mean...that place is a SNF. I imagine they have trouble finding anyone to work there in the best of times. We are definitely not overwhelmed over here. There is likely a dearth of individuals wanting to work at that specific location but overall things aren't that bad, just kind of annoying.

Share this post


Link to post
Share on other sites

You mean their blatant optimism?  Face it.  Individuals who are likely to buy those shirts are likely the ones who are gonna die from it.

Share this post


Link to post
Share on other sites

In Indiana we are in the initial stages of the outbreak, I was in attendance to the first patient death in the state this morning. I am recommending skipping bipap at the infection control meeting I have schedule this afternoon as mentioned in the OP. I was wondering if you all had insight as to infection control procedures being adopted due to limited resources, specifically for aerosol producing procedures. Any input, even anecdotal, would be appreciated.

Share this post


Link to post
Share on other sites

Dom,

That death hasn't been reported on ISDH's website yet.  What hospital?  I'm curious because I'll be at work in the ED at my critical access hospital near the Illinois border on Sat.

Share this post


Link to post
Share on other sites

It is in Indianapolis. The number of suspect patients in this hospital alone is getting close to 50, only 2 are in critical condition. I was surprised to see that the the number had not been updated as the confirmed cases were. I am sure that since it is the first death in state there will be a delay in releasing the info

 

Edited by DomRRTtoPA
there was a news conference 10 min after this posting.

Share this post


Link to post
Share on other sites

The state is getting 50,000 rapid tests with a 3-4 hour turn around whenever they decide to make the delivery this week. At least that is the latest info that I received. Symptomatic patients are not being counted as confirmed until tested. So far we have treated the crit pts with plaquenil, remdesivir was approved but did not arrive before the pt expired and use of the ards.net protocol (proning was inappropriate due to cardiac instability). Many of the things listed in the OP are accurate and appropriate based off my limited experience. I have spent some time in the ED and things have been crazy. No visitor policy, people being turned away at the door for flu like symptoms, supply shortages, elimination of all aerosol treatments, you name it. Stay safe.

Share this post


Link to post
Share on other sites

IBCC podcast on Covid pretty much echoes what OP posted in case anyone wants it in an audio format.

Share this post


Link to post
Share on other sites
2 hours ago, dphy83 said:

IBCC podcast on Covid pretty much echoes what OP posted in case anyone wants it in an audio format.

URL for the uninitiated?

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Similar Content

    • By anaskouk
      Hey good people! I hope you’re all well and healthy during this COVID-19 outbreak. Just wanted to start this early and see your progress on the 2020-21 PA applications!
    • By Car93
      Hello Everyone,
      Is anyone aware of any virtual shadowing opportunities through zoom or any other video platform during this COVID-19 Pandemic?
    • By lncpeter
      I thought it would be helpful to spread the trial information regarding an actively enrolling nationwide pre-exposure prophylaxis with weekly low-dose hydroxychloroquine (website: covidprep.umn.edu). Neat study design with eligibility determination, enrollment, and follow-up online as well as FedEx shipment of the medication. UMN also has a post-exposure prophylaxis trial ongoing, more information at covidpep.umn.edu.
       


      This is a national, internet-based, randomized, double-blinded, placebo-controlled, prospective clinical trial examining the effectiveness of low-dose weekly hydroxychloroquine (HCQ) in preventing COVID-19 infection in high risk healthcare workers. Please find attached trial information sheet and enrollment eligibility email link. Trial information can also be found on Pre-exposure Prophylaxis for SARS-Coronavirus-2 - Full Text View - ClinicalTrials.gov. Feel free to share the trial information with your colleagues, academic connections, and through social media.

      We hypothesized that weekly HCQ (same dose as the well-tolerated anti-malarial prophylactic dose) will decrease the risk of infection, and if infected, decrease the severity of the infection. This hypothesis is based on HCQ's mechanism of action on the endosomal entry pathway of SARS-CoV-2, preliminary clinical data of HCQ in COVID-19 treatment, in vitro antiviral properties, HCQ's high volumes of distribution resulting in high target organ (e.g. lung) steady state concentrations, and HCQ's known safety profile at its weekly dosage.

      The trial will randomize participants into two treatment arms (once weekly dosing or twice weekly) and one placebo arm. Prophylaxis duration will be up to 12 weeks. Recruitment goal is set at 3,500 participants. Eligibility determination, enrollment, and weekly follow-up as well as post-trial follow-up will all be performed online, with no clinic visit or direct human contact. Eligible participants will receive overnight shipment of the medication vs. placebo. Primary endpoint is clinical or laboratory diagnosis of COVID-19.

      Healthcare workers at high risk of COVID-19 exposure will be included in the study. People with active COVID-19 or suspected infection will be excluded and re-directed to other ongoing clinical trials. People with retinal disease, chronic kidney disease, G6PD deficiency, concurrent use of HCQ, HCQ allergy, on medication with potential QT prolongation, or on medication with known significant drug-drug interaction will be excluded.

      We would like to know the answer sooner rather than later. And you can help us by spreading the trial information. If HCQ were truly prophylactic, we will be protecting our brave front-liners not only in the hospital but also from community asymptomatic spread. I would think protecting our critical medical staff is just as important as procuring PPE, ventilators, and bed capacity.
    • By rookiejay
      I wish we had Telemed as a specialty topic 
      I have been looking for work in Temed for years. The AAPA is now pushing to get us into the role and a new website 
      "Telehealth
      Many PAs have asked about opportunities in virtual medicine and telehealth. The Medicare program reimburses PAs for providing all covered telehealth services in the same manner as physicians. In response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services temporarily expanded telehealth and telemedicine services to enable beneficiaries to receive a wider range of healthcare services without having to travel to an office, clinic, or health care facility. PAs are fully included in the telehealth and telemedicine expansion program. PAs can find out more information about telehealth, telemedicine, and reimbursement at AAPA’s Reimbursement website. They may also be interested in joining AAPA’s special interest group, PAs in Virtual Medicine and Telemedicine (PAVMT)."
      https://www.pavmt.org/
      for PA interested in Telemed
       
×
×
  • Create New...

Important Information

Welcome to the Physician Assistant Forum! This website uses cookies to ensure you get the best experience on our website. Learn More